Most CD3-targeted pan-T-cell stimulators at the clinical phase are designed to treat blood tumors, such as targeting CD19 and CD20 for non-Hodgkin lymphoma (NHL), targeting B cell maturation antigen (BCMA), GPRC5D and CD38 for multiple myeloma (MM), targeting CD33, CD123, and CLEC12A for acute myeloid leukemia (AML) (162). Here, TNFRSF17 is linked to hematopoietic and lymphoid system neoplasm.